FXI Inhibitors: A New Frontier in Anticoagulation Therapy

As factor XI (FXI) inhibitors emerge as a promising new class of anticoagulants, healthcare professionals must be prepared to understand their evolving role in patient care. Join the Society of Critical Care Medicine (SCCM), in partnership with the Neuroscience Section, for an expert-led discussion on the latest developments in anticoagulation therapy.

Designed for clinicians who manage patients receiving anticoagulation therapy or who treat anticoagulation-associated bleeding, this webcast will explore the clinical implications of these agents, review the evidence supporting their use, and discuss practical considerations for patient management.

Thursday, September 10, 2026
1:00 p.m. – 2:00 p.m. Central Time

Register Now 

Please log in or create an account before clicking Register Now.
To log in or create an account, click here or navigate to the menu bar at the top of the page, 
then select Log In and Sign In/Sign Up.

SCCM members receive FREE registration. Not a member? Join today!

Can't make the live event? Register anyway and receive a link to the recording.

Learning Objectives

• Understand the rationale behind the FXI inhibitor category of anticoagulants and the pharmacology of drugs in this class
• Critically reevaluate the primary literature that explores the efficacy and safety of FXI inhibitors
• Describe the management of patients taking FXI inhibitors who require urgent surgery or present with major bleeding

Practice Gap Addressed
FXI inhibitors represent an emerging class of anticoagulants that are being evaluated across a wide range of clinical indications, including venous thromboembolism prevention, stroke and systemic embolism prevention in atrial fibrillation, and secondary prevention following ischemic stroke or myocardial infarction. With multiple agents currently advancing through phase II and phase III of clinical trials, FXI inhibitors have the potential to significantly influence anticoagulation management across diverse patient populations.

As these therapies are used more often in clinical practice, healthcare professionals must understand their unique pharmacologic properties, anticipated clinical benefits, and potential safety concerns. A key knowledge gap exists regarding the management of patients receiving FXI inhibitors who develop bleeding complications or require invasive procedures, particularly given the limited clinical experience and lack of established reversal strategies for this drug class. This webcast will address these gaps by reviewing the current evidence and discussing practical approaches to the management of patients treated with FXI inhibitors in perioperative settings and in the context of minor and major bleeding events.